ArticleBrain and behavior2025
Immune Cell Proteins and Parkinson's Disease: A Mendelian Randomization Analysis of Causal Associations.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dapagliflozin ameliorates motor deficits in a Parkinson's disease model induced by 6-OHDA: An integrative in vivo and in silico approach from α-synuclein/A2AAR/TH/TNF-α to APAF-1/caspase-3 modulation.Inflammopharmacology · 2026Article
- The Mediation of Circulating Inflammatory Proteins in the Causal Pathway From Immune Cells to Delirium.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe neuroimmune interaction mechanisms of neurodegenerative diseases have received increasing attention. Parkinson's disease (PD) is the second most common neurodegenerative disease, with potential immunoregulatory abnormalities. However, the causal roles of specific immune cell proteins remain unclear.
methodsWe obtained PD and immune cell protein data from an open and free genome-wide association study (GWAS) for subsequent analysis. Two-sample MR analyses with inverse-variance weighted (IVW), MR-Egger regression, weighted median, and weighted mode methods were used to evaluate the causal effects. Sensitivity analyses incorporated Cochran's Q test for SNP heterogeneity (prioritizing IVW estimates when present) alongside MR-Egger intercept and leave-one-out evaluations to address horizontal pleiotropy.
resultsThe IVW analysis revealed that the genetically predicted level of three immune cell proteins per standard-deviation increase was positively associated with PD, including CD38 (OR = 1.13, 95%CI: 1.05-1.22, P = 0.001), FcγRIIIB (OR = 1.06, 95%CI: 1.01-1.11, P = 0.019), and CUL4B (OR = 1.11, 95% CI: 1.00-1.20, P = 0.012). The IVW analysis also revealed that the genetically predicted level of ADAMTSs per standard-deviation increase was inversely associated with PD (OR = 0.89, 95% CI: 0.81-0.98, P = 0.013).
conclusionsWe demonstrate that CD38, FcγRIIIB, and CUL4B are risk factors for PD, whereas ADAMTSs is a protective factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.